Biotechnology News and Industry Updates
Merck raises 2026 profit guidance as Bio-Techne deal and core operations lift outlook
Merck KGaA is lifting its 2026 outlook again as stronger operating trends and acquisition support improve visibility for the German group's full-year performance. The revised forecast marks the ...
Gene therapy sector seeks more durable financing model
Cell and gene therapy is delivering potentially transformative treatments for rare diseases, but its commercial model remains under pressure as investors question how reliably companies can scale ...
AI start-ups accelerate company building with near-zero staff
Advances in AI coding and task automation are reshaping how start-ups are formed, letting founders launch products and even research operations with minimal capital and few or no employees. The ...
Citi sees China offshore fundraising broaden into biotech and advanced manufacturing
Chinese companies' offshore fundraising drive is expected to continue into 2027 as deal flow expands beyond artificial-intelligence hardware. Citigroup says activity is increasingly supported by ...
Moderna sees cancer vaccine expansion as major oncology growth opportunity
Moderna is pushing beyond treatment into cancer prevention as it develops personalised mRNA vaccines for high-risk patients. The company says the approach could eventually extend from melanoma ...
Windward Bio targets up to $1 billion valuation in U.S. IPO
Biotech issuance in the U.S. remains active into November, with healthcare companies continuing to draw investor interest despite uneven broader market conditions. Swiss drug developer Windward ...
Colossal Biosciences sues ex-executive over alleged trade secret theft
Colossal Biosciences is escalating a legal dispute over its gene-editing research as it accuses a former senior employee of taking confidential information after leaving the company. The lawsuit ...
Moderna raises 2026 revenue growth outlook after Q3 earnings beat
Momentum from newer products and broader geographic sales is strengthening Moderna's 2026 performance as the biotech company lifts its full-year revenue growth forecast. The company now expects ...
UK sovereign AI fund backs Potential Sciences in chemistry AI funding round
Britain is stepping up support for domestic AI companies working on industrial and scientific applications, with a new investment in drug discovery startup Potential Sciences. The company says its ...
AbbVie expands Oxford R&D operations with £120 million UK investment
AbbVie is expanding its research footprint in Oxford with a new facility tied to an investment of more than £120 million in the UK. The move adds capacity in immunology, neuroscience and oncology ...
Genmab trial wins support shift toward owning more cancer drugs
A run of late-stage cancer trial successes is strengthening Genmab's strategy to keep greater control of the medicines it develops and sells. The Danish biotech's shares have doubled in three ...
Formation Bio raises $600 million for AI-driven drug development expansion
Biotech companies are under pressure to cut the high cost and long timelines of bringing new medicines to market. Formation Bio has raised $600 million to expand its drug development model, which ...
Molecular Partners cuts workforce to refocus on radiotherapeutic medicines
Swiss biotech company Molecular Partners is shrinking its operations as it sharpens its strategy around targeted radiotherapy. The planned job cuts affect up to 55 roles and are due to be ...
U.S. biotech IPOs outpace broader market slowdown, but returns remain risky
A weak market for new listings in 2026 is giving way to a notable exception in biotechnology, where companies continue to reach U.S. exchanges despite delays and withdrawals in other sectors. The ...
U.S. adds three Chinese genomics firms to forced labor import ban list
Washington is tightening trade restrictions tied to alleged human rights abuses in China's Xinjiang region by blocking imports from three genomics companies. The move places BGI Genomics, MGI Tech ...
Noubar Afeyan seeks next biotech breakthrough beyond Moderna
After helping build Moderna into one of biotechnology's most valuable companies, co-founder Noubar Afeyan is directing fresh capital toward experimental ideas from his own scientific teams. The ...
Sandoz cuts sales outlook, raises profit margin forecast after biosimilar supply constraints
Short-term supply constraints in biosimilars are weighing on Sandoz's third-quarter performance and prompting the Swiss drugmaker to revise its full-year targets. The company now expects slower ...
Moderna co-founder pursues next biotech breakthrough
After helping build one of biotech's biggest success stories, Noubar Afeyan is continuing to back high-risk science through ideas generated by his own research teams. The strategy reflects a ...
China resumes bull semen imports under elite quality rules
China is reopening imports of cattle genetics after years of disruption, with shipments returning from Australia and Canada as producers seek to lift beef and dairy output. The restart comes with ...
Aspen Neuroscience, Bambusa Therapeutics launch U.S. IPO roadshows as biotech issuance stays active
Biotechnology listings continue to outpace other sectors in this fall's subdued new-issue market, with two drug developers moving ahead with investor marketing on Monday. Aspen Neuroscience and ...
Haemanthus draws investor scrutiny as startup holds patent but no commercial diagnostic product
Public attention around Billy Evans is shifting from a high-profile documentary to the business claims of his Austin startup, Haemanthus. The company says it is developing laser-based disease ...
